Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6725068 | 0.88 | LMNA (0.46) | LMNAMAPTHRH3CCR5 | |
| SCHEMBL6724623 | 0.87 | KMT2A (0.53) | LMNAMAPTHRH3POLBKDM4E | |
| SCHEMBL6733614 | 0.87 | HRH3 (0.45) | LMNAMAPTHRH3MAOBCCR5 | |
| SCHEMBL6726042 | 0.87 | CCR5 (0.50) | LMNAMAPTHRH3ALDH1A1CCR5 | |
| SCHEMBL6725991 | 0.85 | LMNA (0.47) | LMNAMAPTHRH3KDM4ESMN1; SMN2 | |
| SCHEMBL6729282 | 0.81 | LMNA (0.43) | LMNAMAPTHRH3KDM4ESMN1; SMN2 | |
| SCHEMBL6726011 | 0.81 | EPHX2 (0.46) | LMNAHRH3POLBSMN1; SMN2 | |
| SCHEMBL6725701 | 0.81 | CCR5 (0.52) | LMNAMAPTCCR5 | |
| SCHEMBL6733435 | 0.80 | HTR2A (0.46) | LMNAHRH3KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6726619 | 0.80 | HRH3 (0.47) | LMNAHRH3KDM4ESMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | PIERRE FABRE MEDICAMENT (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6583159-B1 | Myocardial ischemia; cytoprotective properties | PIERRE FABRE MEDICAMENT (FR) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | AQP1, SLCO2A1, SLCO2B1 | LMNA 3830/4885MAPT 4509/4885HRH3 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.